Drug intelligence / Profile preview

Trop-1 vaccine

Development stage: Preclinical
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics

Overview

Trop-1 vaccine is an experimental immunotherapeutic vaccine designed to target breast cancer. It utilizes genetically modified fibroblast cells that express the tumor-associated calcium signal transducer-1 (Trop-1) antigen, along with interleukin-2 (IL-2) and allogeneic MHC class I H-2K(b)-determinants. This vaccine aims to induce a CD8+ cell-mediated immune response against breast cancer cells, which has been shown to inhibit tumor growth and prolong survival in mouse models of breast cancer.

Targets

EPCAM (Epithelial cell adhesion molecule)

Beyond the preview

Go deeper on Trop-1 vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Trop-1 vaccine.

Explore the full profile